Case Study: In Re Rigel Pharma Securities Litigation

Law360, New York (September 25, 2012, 2:21 PM EDT) -- On Sept. 6, 2012, the United States Court of Appeals for the Ninth Circuit issued a decision in In re Rigel Pharmaceutical Securities Litigation, No. 10-17619, which addressed the question of “whether statements concerning statistical results of a clinical trial may be considered false or misleading under Rule 10b-5 because the statistical methodology that produced those results was not the best or most acceptable methodology.” The court answered in the negative, holding that allegations that a pharmaceutical company used an imperfect methodology to present its clinical...
To view the full article, register now.